ArticleFrontiers in oncology2025
A novel model for predicting prognosis in pancreatic cancer patients: a retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer is notoriously associated with a poor prognosis and limited survival. We aim to develop a simple and accessible model that can accurately predict the prognosis of pancreatic cancer patients. Methods: This study retrospectively analyzed the blood indicators and overall survival of 500 pancreatic cancer patients. The median value was used as the cutoff for univariate and multivariate analyses. To address the limitations of the median value, receiver operating characteristic analysis was performed, and the optimal cutoff value (the highest Youden index) was determined, followed by univariate and multivariate analyses. Prognostic LASSO coefficient screening was performed to establish a pancreatic cancer prognostic prediction model. Risk factor diagram, Kaplan-Meier curve and prognostic calibration curve were plotted to validate the efficacy of the model. Results: Multivariate regression analysis showed that neutrophils (hazard ratio (HR) = 1.416, 95% confidence interval (CI) = 1.037-1.932,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.